5 New Stock Picks of Billionaire Stanley Druckenmiller

3. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotech firm. Securities filings show that Duquesne Capital owned 259,941 shares in the company at the end of the third quarter of 2021 worth $5.9 million, representing 0.19% of the portfolio. 

On September 21, investment advisory Berenberg initiated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stock with a Buy rating and a price target of $37. Analyst Gal Munda issued the ratings update. 

Among the hedge funds being tracked by Insider Monkey, New York-based firm Laurion Capital Management is a leading shareholder in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with 3.9 million shares worth more than $90 million.